Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Therapeutic potential of adipose-derived stem cells for noncommunicable diseases.

Palma G., Gioia LD., Tedesco C., Cignarelli A., Natalicchio A., Laviola L.

Narrative Review on Osteoarthritis, Neuroinflammation, Chronic Inflammation, Immune Modulation, published in J Endocrinol Invest (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Endocrinol Invest (2026)
Country
Italy
Reported sample size
—
Source database
PubMed
PMID
41484409
DOI
10.1007/s40618-025-02797-w

Abstract (original English)

PURPOSE: The progressive increase in life expectancy has been accompanied by a growing burden of chronic degenerative noncommunicable diseases (NCDs), with major consequences for quality of life and healthcare systems. This scenario underscores the need for innovative therapeutic strategies aimed at preserving organ function and metabolic homeostasis. Adipose-derived stem/stromal cells (ASCs) have emerged as a promising tool in regenerative medicine due to their multipotency, immunomodulatory properties, and paracrine activity. METHODS: We reviewed available preclinical and clinical evidence supporting the therapeutic potential of ASCs in chronic noncommunicable diseases. The analysis focused on ASC biology, mechanisms of action, and current clinical applications, with particular attention to metabolic and endocrine disorders, while also considering cardiovascular, musculoskeletal, neurodegenerative, and other chronic degenerative conditions. RESULTS: Preclinical and clinical studies indicate that ASCs may contribute to tissue repair and functional recovery through differentiation capacity and paracrine signaling, including anti-inflammatory, angiogenic, and cytoprotective effects. In metabolic and endocrine diseases, ASCs have shown potential to improve insulin sensitivity, support pancreatic function, and mitigate chronic metabolic complications. Additional therapeutic applic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAdipose TissueNoncommunicable DiseasesAnimalsRegenerative MedicineStem Cell TransplantationStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research